A breast cancer therapy that requires just one shot of radiotherapy is as effective as traditional radiotherapy, and avoids potential damage to nearby organs, according to a paper by UCL experts.
The results, published in the British Journal of Cancer, mean that eight out of ten patients who receive the treatment, TARGIT-IORT, will not need a long course of post-operative external beam radiotherapy (EBRT). These results strengthen and expand previously published outcomes.
Patients who received the treatment are less likely to go on to experience fatal cardiovascular disease such as heart attacks, lung problems or other cancers. As well as avoiding scattered radiation from EBRT that can damage nearby vital organs, delivering TARGIT-IORT during the lumpectomy procedure seems to lower the likelihood of death if patients do go on to develop cardiovascular disease, protecting in a drug-like manner. This was the case even when EBRT was also given post-operatively, and is thought to be because the treatment changes the microenvironment in the lumpectomy wound.
The researchers say that delivering radiation immediately to the site where the tumour was can reduce the adverse effects of surgical trauma make the site less conducive for cancer growth and could have an 'abscopal' (distant) effect. This is where a treatment such as radiotherapy has a positive effect on tissue away from the operation site, which is increasingly recognised as a beneficial immunological action.
Previous studies have shown that the treatment has fewer radiation-related side effects compared with conventional whole breast radiotherapy, with less pain, a superior cosmetic outcome with fewer changes to the breast as a whole and a better quality of life.
Lead author Professor Jayant Vaidya (UCL Surgery & Interventional Science) said: "With TARGIT-IORT, women can have their surgery and radiation treatment for breast cancer at the same time. This reduces the amount of time spent in hospital and enables women to recover more quickly, meaning they can get back to their lives more quickly."
TARGIT-IORT is delivered immediately after tumour removal (lumpectomy), and under the same anaesthetic, via a small ball-shaped device placed inside the breast, directly where the cancer had been. The single-dose treatment lasts for around 20-30 minutes and replaces the need for extra hospital visits in eight out of ten cases.
Further tumour subgroup analysis also found that there was a significant overall survival benefit with TARGIT-IORT in patients with grade 1 or 2 cancer.
Professor Vaidya added: "These new results make it clear that the TARGIT-IORT is effective in all tumour subgroups of invasive duct cancer, the most common type of breast cancer. Our new online tool can help clinicians make a decision about additional radiotherapy (recommended in a small proportion of cases) for each individual patient.
"The finding that fewer deaths are from the avoidance of scattered radiation and the possible abscopal effect of TARGI-IORT is important and should fuel further research, opening doors to new treatments."
For the clinical trial, which started in March 2000, 2,298 women aged 45 or over with invasive breast cancer and a tumour up to 3.5cm in diameter were randomly assigned to receive either TARGIT-IORT during lumpectomy or post-operative EBRT.
The trial was designed and run from UCL, involved 32 hospitals and medical centres in ten countries: the UK, France, Germany, Italy, Norway, Poland, Switzerland, the USA, Canada and Australia.
Professor Michael Baum (UCL Surgery & Interventional Science) said: These results are the highest level of evidence proving not only the effectiveness of TARGIT-IORT but confirming that it avoids deaths from other causes.
"The new data is biologically very interesting and the new tools will make its application in routine clinical practice much easier. I am pleased that it will benefit thousands of breast cancer patients around the world."
Professor Jeffrey S Tobias (Professor of Clinical Oncology, UCL and UCLH) said: With "TARGIT-IORT, the majority of patients presenting with early localised breast cancer will never need any further radiotherapy.
"They will avoid all the side effects of whole breast radiotherapy. The chance of remaining free of local recurrence (in the breast itself) is the same as with traditional treatment, but our new analysis shows that even if they do get a local relapse, it will not detract from an excellent prognosis - as good as not having a relapse - a rather different state of affairs from the more serious outlook if this were to happen after EBRT."
To date, 45,000 patients in 260 centres in 38 countries have received TARGIT-IORT). The clinicians hope that following the latest results, more patients can be offered the treatment both in the UK and around the world instead of EBRT.
###
Additional material:
Paper published in the British Medical Journal in 2020, upon which this paper expands: https:/
A short video explanation: https:/
An explanatory blog: https:/
For more information about the treatment: https:/
Funding for the trial was provided by the National Institute for Health Research (NIHR) Health Technology Assessment Programme, UCL Comprehensive Biomedical Research Centre and Cancer Research UK.
Notes to Editors
For more information or to speak to the researchers involved, please contact
Jane Bolger, UCL Media Relations. T: +44 (0) 20 3108 9040 / +44 (0)7733 261 477. E: j.bolger@ucl.ac.uk
Professor Jayant Vaidya. T; +44 7801418072 and Prof Tobias +44 7814702063
Jayant S. Vaidya, Max Bulsara, Michael Baum, Frederik Wenz, Samuele Massarut, Steffi Pigorsch, Michael Alvarado, Michael Douek, Christobel Saunders, Henrik Flyger, Wolfgang Eiermann, Chris Brew-Graves, Norman R. Williams, Ingrid Potyka, Nicholas Roberts, Marcelle Bernstein, Douglas Brown, Elena Sperk, Siobhan Laws, Marc Sütterlin, Tammy Corica, Steinar Lundgren, Dennis Holmes, Lorenzo Vinante, Fernando Bozza, Montserrat Pazos, Magali Le Blanc-Onfroy, Günther Gruber, Wojciech Polkowski, Konstantin J. Dedes, Marcus Niewald, Jens Blohmer, David McReady, Richard Hoefer, Pond Keleman, Gloria Petralia, Mary Falzon, David Joseph, Jeffrey S. Tobias, 'New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer' is published in British Journal of Cancer.
The DOI for this paper is https:/
About UCL (University College London) - London's Global University
UCL is a diverse community with the freedom to challenge and think differently.
Our community of more than 41,500 students from 150 countries and over 12,500 staff pursues academic excellence, breaks boundaries and makes a positive impact on real world problems.
We are consistently ranked among the top 10 universities in the world and are one of only a handful of institutions rated as having the strongest academic reputation and the broadest research impact.
We have a progressive and integrated approach to our teaching and research - championing innovation, creativity and cross-disciplinary working. We teach our students how to think, not what to think, and see them as partners, collaborators and contributors.
For almost 200 years, we are proud to have opened higher education to students from a wide range of backgrounds and to change the way we create and share knowledge.
We were the first in England to welcome women to university education and that courageous attitude and disruptive spirit is still alive today. We are UCL.
http://www.
Find out how UCL is helping lead the global fight against COVID-19 http://www.
"breast" - Google News
May 28, 2021 at 07:01PM
https://ift.tt/2R0CcRf
Pioneering single-dose radiotherapy for breast cancer treatment - EurekAlert
"breast" - Google News
https://ift.tt/2ImtPYC
https://ift.tt/2Wle22m
Bagikan Berita Ini
0 Response to "Pioneering single-dose radiotherapy for breast cancer treatment - EurekAlert"
Post a Comment